Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel is supported with funding from Prothena (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

EHA 2022 | Unmet needs in AL amyloidosis: treatment options for R/R patients

Jahanzaib Khwaja • 10 Jun 2022
EHA 2022
Amyloidosis Rare Diseases Antibodies Belantamab mafodotin

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, comments on unmet needs in patients with relapsed/refractory (R/R) AL amyloidosis. Dr Khwaja explains that there are few clinical trials in this setting, and patients have limited treatment options. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Jahanzaib Khwaja

Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
1:48
Daratumumab, bortezomib, thalidomide & dexamethasone in treatment-naive systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment
1:50
Approaching the treatment of patients with AL amyloidosis who relapse after dara-based treatment
Jahanzaib Khwaja • 14 Jun 2025
The impact of ethnicity on the risk stratification of systemic AL amyloidosis
1:53
The impact of ethnicity on the risk stratification of systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025
Identification of an ultra-poor risk
2:31
Identification of an ultra-poor risk "Mayo Stage IIIC" subgroup in systemic AL amyloidosis
Jahanzaib Khwaja • 14 Jun 2025

Related Videos

Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
2:08
Federated learning to train generative AI models for diagnosis & prognosis of hematological diseases
Jahanzaib Khwaja • 7 Dec 2025
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
2:25
Initial results from the NEXICART-2 trial of BCMA-directed CAR-T (NXC-201) in R/R AL amyloidosis
Jahanzaib Khwaja • 5 Dec 2025
Investigating novel therapeutic approaches for T-cell lymphoma
1:01
Investigating novel therapeutic approaches for T-cell lymphoma
Jahanzaib Khwaja • 8 Dec 2025
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
3:45
Phase II REVIVE trial: teclistamab plus daratumumab for high-risk smoldering multiple myeloma
Jahanzaib Khwaja • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals